Representation of Women Authors in Trials of Lipid‐Lowering Therapy

Subramanian, C. R.; Khan, Safi U.; Lone, Ahmad Naeem; Reza, Nosheen; DeFilippis, Ersilia M.; Gulati, Martha; Michos, Erin D.

doi:10.1161/jaha.121.020663

Cited by 7 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Women in any author position represented less than a third of publications, and an even smaller proportion of first and senior female authors. An analysis of research articles in four major cardiology journals early in the COVID-19 pandemic revealed that representation of women as first or senior authors of any article type of non-COVID-related papers increased from March to June 2020 compared to 2019 [ 4 ]. In COVID-19-related cardiology papers, women represented similar proportions of first and senior authors to non-COVID-related papers; however, they were significantly less likely to be first authors of COVID-19-related original research articles.…”

Section: Discussionmentioning

confidence: 99%

“…During the recent COVID-19 pandemic, despite rapidly accelerating rates of COVID-19-related publications, the proportion of male authors continued to exceed their female colleagues in cardiology-related research [ 3 ]. Early in the pandemic, a study of a subset of four high-impact journals found that the proportions of female first or senior authors in COVID-19-related manuscripts were slightly higher compared with authorship trends in 2019 [ 4 ]. The updated cumulative impact of the ongoing pandemic on gender authorship disparities remains unclear.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gender Disparities in Cardiology-Related COVID-19 Publications

et al. 2021

View full text Add to dashboard Cite

Introduction: Female authors are underrepresented in cardiology journals, although prior work suggested improvement in reducing disparities over time. Early in the recent COVID-19 pandemic, female authorship continued to lag that of their male counterparts despite a surge in publications. The cumulative impact of the COVID-19 pandemic on authorship gender disparities remains unclear. We aimed to characterize gender disparities in COVID-19-related cardiology publications across the duration of the ongoing pandemic. Methods: We retrospectively analyzed COVID-19-related research articles published in the top 20 impact factor cardiology journals between March and June 2021. Gender representation data were extracted for any author, first authors, and senior authors.Results: We found that 841 articles were related to COVID-19, with a total of 5586 authors and an average of 42 articles per journal. Less than a third (29.9%) of the total authors from publications were women. Women represented a smaller proportion of first authors (21.3%) and senior authors (16.4%). Conclusions: Female authorship has continued to lag male authorship for the duration of the ongoing COVID-19 pandemic. The pandemic may have impeded progress in reducing gender disparities in academic cardiology publications. The low proportions of first and senior female authors may reflect the impact of the pandemic on women in cardiology in leadership domains.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Gender Disparities in Cardiology-Related COVID-19 Publications

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Despite evidence-based guidelines on management of HLD, 52.3 million American women (40.4%) have total cholesterol (TC) greater than 200 mg/dL [1]. Women are more likely to have high cholesterol than men [1,3], yet they comprise only 28% of patients in large trials on LLT [4,5]. Women are also less likely to be treated for high choles-terol; lipid control is seen in 50.5% of women compared to 63.3% of men [3].…”

Section: Introductionmentioning

confidence: 99%

Review of Lipid-Lowering Therapy in Women from Reproductive to Postmenopausal Years

Witting¹,

Devareddy²,

Rodríguez³

2022

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Although cardiovascular disease (CVD) is the leading cause of death in women, cardiovascular risk factors remain underrecognized and undertreated. Hyperlipidemia is one of the leading modifiable risk factors for CVD. Statins are the mainstay of lipid lowering therapy (LLT), with additional agents such as ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors as additive or alternative therapies. Clinical trials have demonstrated that these LLTs are equally efficacious in lipid lowering and cardiovascular risk reduction in women as they are in men. Although the data on statin teratogenicity is evolving, in times of pregnancy or attempted pregnancy, most lipid-lowering agents are generally avoided due to lack of high-quality safety data. This leads to limited treatment options in pregnant women with hyperlipidemia or cardiovascular disease. During the perimenopausal period, the mainstay of lipid management remains consistent with guidelines across all ages. Hormone replacement therapy for cardiovascular risk reduction is not recommended. Future research is warranted to target sex-based disparities in LLT initiation and persistence across the life course.

show abstract

“…Women authors comprised <20% of lipid‐lowering therapy trials between 1994 and 2018. 4 The median proportion of women authors per publication was 20% in United States heart failure guidelines, 14% in European heart failure guidelines, and 11% in heart failure trials. 2 In gastroenterology, <30% of women were first authors, and <15% served as a senior author between 1992 and 2012.…”

mentioning

confidence: 99%